Interstitial lung disease was reported in 4 of 1,570 (0.25%) patients with advanced colorectal cancer [3]. There have also been reports of interstitial pneumonitis with non-cardiogenic pulmonary edema [8]. The use of cetuximab in combination

regimens potentially clouds side effect profiles. Pulmonary complications in the setting of chemotherapy lead to increased morbidity and severe reactions are associated with mortality. Cetuximab, like many other cancer therapies, has been GSK1210151A mouse demonstrated to cause a wide range of respiratory effects from mild dyspnea to a fatality due adverse pulmonary events. The purpose of this investigation is to compile a comprehensive list of pulmonary adverse events in the ACP-196 price setting of therapy with cetuximab published in the literature in order to better characterize the true incidence of these reactions. A better understanding of the prevalence may help the clinician respond appropriately to specific symptom changes during the therapeutic window with a hope of improving patient care. Methods We performed

a MEDLINE™ search of the English Dabrafenib language literature using the search terms: “”cetuximab”" or “”Erbitux”" with limits to include only human studies to develop a complete index of trials or reports. Inclusion criteria were clinical trials, meta-analyses, or randomized controlled trials that included the search terms and cited adverse events. The reference lists from each of these manuscripts were scanned to isolate articles not obtained in the MEDLINE® search to complete our database. Studies were excluded if they did not list adverse events. Data extracted from each report included number of patients, controls, type of cancer, coincident chemotherapy administration, and information regarding pulmonary Sucrase complications. Pulmonary complications included the incidence of symptoms related to the respiratory system including dyspnea, cough, wheezing, pneumonia, hypoxemia, respiratory insufficiency/failure, pulmonary embolus, pleural effusion, and non-specific respiratory disorders. Incidences of these pulmonary complications were obtained from each study’s control group if available and compared between the patients

that received cetuximab and those who did not. Infusion reactions were treated as a separate complication to cetuximab and were not included in this analysis, although in many individuals, symptoms of shortness of breath and chest tightness may be encompassed by this type of reaction [9]. Data Analysis and Statistics Data is presented as the number of patients and percentage receiving the study medication as well as means (± SD) where appropriate. Comparisons between groups were made using Chi-Square or students t-test where appropriate, and statistical significance was set as p < 0.05. Results Using our search criteria defined above, a total of 245 articles were obtained for review. From this complete group, 192 articles were excluded for not meeting inclusion criteria.